本文源自：金融界 大事提醒： 8月28日，天境生物(美东)盘前披露2024财年中报（数据来源于纳斯达克官网，预计披露日期为美国当 地时间，实际披露日期以公司公告为准）。 资料显示，天境公司是一家境外注册成立的离岸控股母公司,通过境内子公司天境生物开展业务。天境 生物是一家聚焦于肿瘤免疫和自身免疫领域的创新生物药企业,公司高度专注于在全球范围内开发具 有"全球首创"和"同类最优"潜力的创新生物药。公司的使命是研制具有突破性的创新生物药,填补临床 治疗需求的空白,并且切实提高全球患者的生存质量。为了实现这个目标,公司正在努力成为一家扎根中 国、面向全球的领先生物医药公司。 8月14日，天境生物(IMAB)盘中上涨10.61%，截至21:37，报4.69美元/股，成交223.05万美元，总市值 5.39亿美元。 财务数据显示，截至2023年12月31日，天境生物收入总额2764.4万人民币，同比增长112.48%；归母净 利润-14.66亿人民币，同比增长41.54%。 作者：行情君 ...

Core Viewpoint - Tianjing Bio (IMAB) has shown significant financial growth, with a notable increase in revenue and a focus on innovative biopharmaceuticals in the oncology and autoimmune sectors [1][2]. Financial Performance - As of December 31, 2023, Tianjing Bio reported total revenue of 27.644 million RMB, representing a year-on-year increase of 112.48% [1]. - The company's net profit attributable to shareholders was -1.466 billion RMB, which reflects a year-on-year improvement of 41.54% [1]. Company Overview - Tianjing Bio is an offshore holding company that operates through its domestic subsidiary, focusing on developing innovative biopharmaceuticals with "first-in-class" and "best-in-class" potential [2]. - The company's mission is to create groundbreaking biopharmaceuticals that address unmet clinical needs and improve the quality of life for patients globally [2]. - Tianjing Bio aims to establish itself as a leading biopharmaceutical company rooted in China and oriented towards global markets [2].

Core Viewpoint - Tianjing Bio (IMAB) has shown significant financial growth, with a notable increase in revenue and a focus on innovative biopharmaceuticals in the oncology and autoimmune sectors [1][2]. Financial Performance - As of December 31, 2023, Tianjing Bio reported total revenue of 27.644 million RMB, representing a year-on-year growth of 112.48% [1]. - The company's net profit attributable to shareholders was -1.466 billion RMB, which reflects a year-on-year increase of 41.54% [1]. Company Overview - Tianjing Bio is an offshore holding company that operates through its domestic subsidiary, focusing on the development of innovative biopharmaceuticals with "first-in-class" and "best-in-class" potential [2]. - The company's mission is to develop groundbreaking biopharmaceuticals that address unmet clinical needs and improve the quality of life for patients globally [2]. - Tianjing Bio aims to establish itself as a leading biopharmaceutical company rooted in China and oriented towards global markets [2].

Core Viewpoint - Tianjing Bio (IMAB) has shown significant financial growth, with a notable increase in revenue and a focus on innovative biopharmaceuticals in the oncology and autoimmune sectors [1] Financial Performance - As of December 31, 2023, Tianjing Bio reported total revenue of 27.644 million RMB, representing a year-on-year increase of 112.48% [1] - The company's net profit attributable to shareholders was -1.466 billion RMB, which reflects a year-on-year improvement of 41.54% [1] Upcoming Events - Tianjing Bio is scheduled to disclose its fiscal year 2024 mid-term report on August 28, 2023, before the market opens in the Eastern US [1] Company Overview - Tianjing Bio is an offshore holding company that operates through its domestic subsidiary, focusing on the development of innovative biopharmaceuticals with "first-in-class" and "best-in-class" potential [1] - The company's mission is to develop groundbreaking biopharmaceuticals that address unmet clinical needs and improve the quality of life for patients globally [1] - Tianjing Bio aims to establish itself as a leading biopharmaceutical company rooted in China and oriented towards global markets [1]

Core Viewpoint - I-Mab has successfully completed enrollment in the Phase 1b dose expansion cohorts for givastomig, a bispecific antibody targeting Claudin 18.2, ahead of expectations, indicating strong interest and unmet needs in gastric cancer therapy [1][3]. Group 1: Study Details - The Phase 1b study (NCT04900818) is focused on evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of givastomig in combination with nivolumab and mFOLFOX6 for CLDN18.2-positive gastric cancers [2]. - A total of 40 patients were enrolled in the dose expansion cohorts, with two doses being tested: 8 mg/kg and 12 mg/kg [2]. - The primary endpoint of the study is safety, and it exclusively enrolled patients in the U.S. [2]. Group 2: Clinical Data and Results - Data presented at the ESMO GI 2025 indicated an 83% objective response rate (ORR) for givastomig in combination with immunochemotherapy at the selected doses [3][8]. - The response onset was reported to be rapid, durable, and deepened over time, with favorable overall safety [3]. Group 3: Product Overview - Givastomig is a bispecific antibody designed to target Claudin 18.2-positive tumor cells and conditionally activate T cells through the 4-1BB signaling pathway [4][7]. - The drug is being developed for first-line metastatic gastric cancers, with potential applications in other solid tumors [4][7]. Group 4: Development Partnership - Givastomig is being developed through a global partnership with ABL Bio, where I-Mab is the lead party and shares worldwide rights, excluding Greater China and South Korea, equally with ABL Bio [6]. Group 5: Future Expectations - The company expects to release topline results from the Phase 1b study in Q1 2026, following the positive data from the dose escalation phase [8].

Group 1 - The core viewpoint of the news is that Tianjing Biopharma (IMAB) has shown significant financial growth, with a notable increase in revenue and a decrease in net profit loss, indicating potential for future investment opportunities [1][2]. - As of August 8, 2023, Tianjing Biopharma's stock opened at $3.601 per share, reflecting a 2.6% increase, with a total market capitalization of $414 million [1]. - The company's total revenue for the year ending December 31, 2023, was reported at 27.644 million RMB, representing a year-on-year growth of 112.48% [1]. Group 2 - Tianjing Biopharma is focused on developing innovative biopharmaceuticals in the fields of tumor immunology and autoimmune diseases, aiming to create "first-in-class" and "best-in-class" therapies [2]. - The company is set to disclose its fiscal year 2024 mid-term report on August 28, 2023, which is anticipated to provide further insights into its financial performance [2]. - The mission of Tianjing Biopharma is to develop groundbreaking biopharmaceuticals that address unmet clinical needs and improve the quality of life for patients globally [2].

Core Viewpoint - Tianjing Bio (IMAB) has shown significant stock performance and financial growth, indicating potential investment opportunities in the innovative biopharmaceutical sector focused on oncology and autoimmune diseases [1]. Financial Performance - As of December 31, 2023, Tianjing Bio reported total revenue of 27.644 million RMB, representing a year-on-year increase of 112.48% [1]. - The company recorded a net profit attributable to shareholders of -1.466 billion RMB, which is a year-on-year increase of 41.54% [1]. Upcoming Events - Tianjing Bio is scheduled to disclose its fiscal year 2024 mid-term report on August 28, 2023, before the market opens in the Eastern US [1]. Company Overview - Tianjing Bio is an offshore holding company that operates through its domestic subsidiary, focusing on the development of innovative biopharmaceuticals with "first-in-class" and "best-in-class" potential in the global market [1]. - The company's mission is to develop groundbreaking innovative biopharmaceuticals to address unmet clinical needs and improve the quality of life for patients worldwide [1].

Group 1 - The stock price of Tianjing Biological (IMAB) increased by 11.01% on August 6, reaching $3.741 per share, with a trading volume of $4.6017 million and a total market capitalization of $430 million [1] - As of December 31, 2023, Tianjing Biological reported total revenue of 27.644 million RMB, representing a year-on-year growth of 112.48%, while the net profit attributable to the parent company was -1.466 billion RMB, showing a year-on-year increase of 41.54% [1] Group 2 - Tianjing Biological is scheduled to disclose its fiscal year 2024 interim report on August 28, with the actual disclosure date subject to the company's announcement [2] - The company is an offshore holding parent company that operates through its domestic subsidiary, focusing on innovative biopharmaceuticals in the fields of tumor immunity and autoimmune diseases [2] - Tianjing Biological aims to develop innovative biopharmaceuticals with "first-in-class" and "best-in-class" potential globally, striving to fill clinical treatment gaps and improve the quality of life for patients worldwide [2]

Market Overview - On August 5, U.S. stock indices opened high but closed lower, with the Dow Jones down 61.9 points at 44111.74, a decline of 0.14%; the Nasdaq fell 137.03 points to 20916.55, down 0.65%; and the S&P 500 dropped 30.75 points to 6299.19, a decrease of 0.49% [1] - Major tech stocks mostly declined, with Facebook down over 1%, Microsoft down over 1%, Nvidia down nearly 1%, Apple down 0.21%, Google down 0.19%, Tesla down 0.17%, while Amazon rose nearly 1% [3] Pharmaceutical Sector - Pharmaceutical stocks saw significant gains, with Pfizer closing up over 5% and UnitedHealth Group rising over 4% [4] Chinese Stocks - The Nasdaq Golden Dragon China Index fell 0.56%, with mixed performance among popular Chinese stocks. Tianjing Bio surged over 15%, Zhihu rose over 6%, and Canadian Solar increased over 4%. However, companies like Lingzhong Portal fell nearly 20%, Yum China dropped over 6%, and Atour fell over 4% [4] Bond Market - U.S. Treasury yields generally rose, with the benchmark 10-year Treasury yield closing at 4.218% and the more rate-sensitive 2-year Treasury yield at 3.739% [5] Economic Indicators - The ISM reported that the U.S. services PMI for July was 50.1, below the market expectation of 51.5 and the previous month's 50.8, indicating near stagnation in service sector growth. Employment metrics fell from 47.2 to 46.4, the lowest since the pandemic began [6]

Group 1 - The core viewpoint of the articles highlights the financial performance and upcoming reporting of Tianjing Biological (IMAB), indicating a significant revenue growth and a focus on innovative biopharmaceuticals in oncology and autoimmune diseases [1][2][3] Group 2 - As of August 5, Tianjing Biological's stock opened at $3.01 per share, with a market capitalization of $246 million and a trading volume of $496,100 [1] - For the fiscal year ending December 31, 2023, Tianjing Biological reported total revenue of 27.644 million RMB, representing a year-on-year increase of 112.48%, while the net profit attributable to shareholders was -1.466 billion RMB, showing a year-on-year increase of 41.54% [1] - Tianjing Biological is a company focused on developing innovative biopharmaceuticals with "first-in-class" and "best-in-class" potential, aiming to address unmet clinical needs and improve the quality of life for patients globally [2]